logo-loader
RNS
PureTech Health

PureTech Health PLC - PDMR Notification RSU Vesting

RNS Number : 8557M
PureTech Health PLC
17 July 2026
 

17 July 2026

PureTech Health plc

 

PDMR Notifications

 

PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company") a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, announces that awards of restricted share units ("RSUs") granted by PureTech on 26 June 2024 to certain directors and other persons discharging managerial responsibilities ("PDMRs") pursuant to its Performance Share Plan ("PSP") 33% of the shares vested on 26 June 2026 and were subsequently issued to the PDMRs noted below.

Each PDMR received vested ordinary shares (after deduction of shares for payroll taxes) on 14 July 2026. The market price per ordinary share in the Company used to calculate the amount payable to the PDMRs and the amount of shares to be issued to PDMRs was 119.20 pence, being the average closing price of the Company's shares over the three-trading day period immediately prior to issuance, and the exchange rate used to calculate the cash payment and amount of share settlement was £1: $1.34.

The Company's total issued ordinary share capital is 257,927,489 shares after the share issuance to the PDMRs, 14,030,193 shares of which are held in treasury by the Company.

PDMR Notification

 

The information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Eric Elenko

Michael Inbar

Charles Sherwood

2

Reason for the notification

a)

Position/status

Eric Elenko - President

Michael Inbar - Chief Accounting Officer

Charles Sherwood - Chief Operating Officer, General Counsel and Corporate Secretary

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

PureTech Health plc

b)

LEI

213800LVPDNO2Z9T9I39

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary Shares of PureTech Health plc

ISIN GB00BY2Z0H74


b)

Nature of the transaction

Issuance of ordinary shares in net settlement of certain vested RSUs under the PureTech Health Performance Share Plan, after retentions in respect of payroll taxes.

c)

Price(s) and volume(s)

Recipient

Price

Amount

Eric Elenko

0.01 GBP

56,735 ordinary shares

Michael Inbar

0.01 GBP

30,245 ordinary shares

Charles Sherwood

0.01 GBP

37,001 ordinary shares

d)

Aggregated information

-

Aggregated volume

-

Price

Price

Aggregate Volume

0.01 GBP

123,981 ordinary shares

e)

Date of the transaction

14 July 2026

f)

Place of the transaction

London Stock Exchange (XLON)

 

About PureTech Health

PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.

 

For more information, visit www.puretechhealth.com or connect with us on LinkedIn and X (formerly Twitter) @puretechh. 

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGPUWUMUPQGGM
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read